Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310023 · ClinicalTrials.gov registry record
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
A clinical trial, sponsored by Harvard School of Public Health (HSPH).
- Completed
- Registry status
- 5,169
- Enrollment target
NCT01310023: Completed study, sponsored by Harvard School of Public Health (HSPH).
NCT01310023 is a clinical trial that has completed, run by Harvard School of Public Health (HSPH). The registered enrollment target is 5,169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01310023 has completed, sponsored by Harvard School of Public Health (HSPH).
- COMPLETED
- Registry status
- 5,169 participants
- Enrollment target
Study Summary
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Primary Outcome
Assessed via head circumference measurement and medical record review for documented clinical diagnoses of seizures, microcephaly, or other neurologic diagnosis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,169 participants |
| Start Date | 2007-03 |
| Est. Completion | 2025-05-31 |
What the finished NCT01310023 record still lists
NCT01310023 is an observational study that tracks outcomes without assigning an intervention. Its 5,169 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01310023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01310023 about?
NCT01310023 is a clinical study titled "Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women". SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
What is the current status of trial NCT01310023?
This trial is currently completed. The enrollment target is 5,169 participants. The study started on 2007-03. Estimated completion is 2025-05-31.
Who is sponsoring clinical trial NCT01310023?
This trial is sponsored by Harvard School of Public Health (HSPH), which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT06535867 · 5,122 participants
The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia